Literature DB >> 29779436

Early Lupus Project: one-year follow-up of an Italian cohort of patients with systemic lupus erythematosus of recent onset.

G D Sebastiani1, I Prevete1, A Iuliano1, M Piga2, F Iannone3, L Coladonato3, M Govoni4, A Bortoluzzi4, M Mosca5, C Tani5, A Doria6, L Iaccarino6, A Tincani7, M Fredi7, F Conti8, F R Spinelli8, M Galeazzi9, F Bellisai9, A Zanetti10, G Carrara10, C A Scirè10, A Mathieu2.   

Abstract

Objective To describe the clinical and serological features of a prospectively followed cohort of early diagnosed systemic lupus erythematosus (SLE) patients during a one-year follow-up period. Methods SLE patients with disease duration less than 12 months were consecutively enrolled in a multicentre, prospective study. At study entry and then every 6 months, a large panel of data was recorded. Results Of 260 patients enrolled, 185 had at least 12 months of follow-up; of these, 84.3% were female, 92.4% were Caucasians. Mean diagnostic delay was about 20 months; higher values of European Consensus Lupus Activity Measurement (ECLAM) and of organs/systems involved were both associated with shorter diagnostic delay. Clinical and serological parameters improved after study entry. However, patients' quality of life deteriorated and cardiovascular risk factors significantly increased. About one-third of patients with active disease at study entry went into remission (ECLAM = 0). Negative predictors for remission were: oral ulcers, arthritis, low C4, anti-SSB (Ro) antibodies and therapy with mycophenolate. There was a widespread use of glucocorticoids both at baseline and during follow-up. Conclusion Clinical symptoms and serological parameters improve during the first period after diagnosis. However, patients' quality of life deteriorates. The widespread use of glucocorticoids is probably the reason for the early significant increase of some cardiovascular risk factors.

Entities:  

Keywords:  Autoantibody(ies); autoimmune disease; cohort studies; glucocorticoids; systemic lupus erythematosus

Mesh:

Substances:

Year:  2018        PMID: 29779436     DOI: 10.1177/0961203318777112

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  3 in total

1.  The patient's perspective: are quality of life and disease burden a possible treatment target in systemic lupus erythematosus?

Authors:  Anna Kernder; Elena Elefante; Gamal Chehab; Chiara Tani; Marta Mosca; Matthias Schneider
Journal:  Rheumatology (Oxford)       Date:  2020-12-05       Impact factor: 7.580

2.  Prevalence of systemic lupus erythematosus-related symptoms assessed by using the Connective Tissue Disease Screening Questionnaire in a large population-based cohort.

Authors:  Wietske Lambers; Suzanne Arends; Caroline Roozendaal; Elisabeth Brouwer; Hendrika Bootsma; Johanna Westra; Karina de Leeuw
Journal:  Lupus Sci Med       Date:  2021-11

Review 3.  Finding lupus in the ANA haystack.

Authors:  Nancy J Olsen; David R Karp
Journal:  Lupus Sci Med       Date:  2020-02-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.